Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Jackpot Digital (TSXV:JJ): Meet the company revolutionizing casino gaming

What does the future of casino gaming look like? Well, just imagine, for a moment, being on a cruise, playing the tables at the casino, and you hit a patch of rough waters. Well, Jackpot Digital, it seems, has thought of this. They signed a deal in 2017 with Carni...
Brieanna McCutcheon | November 14, 2022 |

Finding the Jackpot in the Electronic Gaming Machine Market

I have an interest in gambling and poker as a venue for some modest entertainment. After all, investing in penny stocks would qualify as gambling, but like any gambler, we look for an edge or advantage. With penny stocks, my edge is many years of experience and a long lis...
Streetwise Reports | March 2, 2018 |

Myovant Sciences Shares Rise on NDA Filing for Uterine Fibroid Combination Therapy Drug

Shares of Myovant Sciences traded 40% higher after the company reported that it has submitted a New Drug Application to the FDA for once-daily relugolix combination tablet for the treatment of women with uterine fibroids. Healthcare company Myovant Sciences Ltd. (...
Streetwise Reports | June 2, 2020 |

Gold Weather Veins in Big Red

The explorer recently released early-stage sampling results for its Golden Triangle property that identifies a "significant gold discovery." Streetwise Reports caught up with Ian Slater, the CEO of Libero Copper and Gold Corp. (LBC:TSX.V:, LBCMF:OTCQB) . Slater is ra...
Streetwise Reports | September 13, 2019 |

Get Lucky! Meet the Premier Esports Betting Platform. For Gamers, By Gamers

(CLICK IMAGE TO PLAY VIDEO) The online e-gaming industry is no longer just a phenomenon, it’s now globally omnipresent and is expected to reach $257 billion dollars in revenue by 2025. In fact, There are more than 2.7 billion video gamers around ...
Dave Jackson | June 10, 2021 |

Exelixis Shares Climb 21% on Positive Phase 3 Advanced Kidney Cancer Study Results

Shares of Exelixis reached a new 52-week high price after the firm reported positive topline results from its Pivotal Phase 3 CheckMate -9ER trial evaluating Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) in previously untreated advanced ...
Streetwise Reports | April 21, 2020 |

A Combination Topping Pattern Is Setting Up

Our research team has highlighted a number of technical and other factors that point to a very real potential of a major market top setting up across the global markets. We've highlighted a number of research articles over the past 30 to 45 days that clearly illustrate our int...
Chris Vermeulen | January 31, 2020 |

Lockdown

Sector expert Michael Ballanger interprets year-end investment tactics by looking back at a childhood encounter. "Gold is money; everything else is credit." —J.P. Morgan My first faithful dog Fido (circa 1963) and I used to play a game years ago before his eyes and ...
Streetwise Reports | November 27, 2019 |

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial

This morning PDS Biotechnology Corp. shares are trading 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection....
Streetwise Reports | October 4, 2019 |

Genprex Shares Soar 250% on FDA Fast Track Designation for Lung Cancer Drug

Genprex's shares spiked 380% higher in morning trading as the company reported that the FDA granted Fast Track Designation for its Oncoprex immunogene therapy in combination with EGFR inhibitor osimertinib. This morning, Genprex Inc. (GNPX:NASDAQ) , which "utilizes a...
Streetwise Reports | January 22, 2020 |
1 2 3 4 5 6 7 8 9 10 ...